Stock 688202 SHANGHAI MEDICILON INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai Medicilon Inc.

Equities

688202

CNE100003NQ8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-05-08 EDT 		5-day change 1st Jan Change
40 CNY -4.15% Intraday chart for Shanghai Medicilon Inc. +13.12% -41.50%
04-28 Shanghai Medicilon Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-02 Tranche Update on Shanghai Medicilon Inc.'s Equity Buyback Plan announced on November 13, 2023. CI

Valuation

Fiscal Period: December 2019 2022 2023 2024 2025
Capitalization 1 3,618 18,612 9,209 5,387 -
Enterprise Value (EV) 1 3,618 18,612 9,209 5,387 5,387
P/E ratio 54.7 x 51.2 x -263 x 22.7 x 18.1 x
Yield - - - - -
Capitalization / Revenue 8.06 x - 6.74 x 2.66 x 2.23 x
EV / Revenue 8.06 x - 6.74 x 2.66 x 2.23 x
EV / EBITDA 38,576,621 x - - - -
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book 3.64 x - 3.67 x 1.82 x 1.67 x
Nbr of stocks (in thousands) 121,520 121,823 134,673 134,673 -
Reference price 2 29.77 152.8 68.38 40.00 40.00
Announcement Date 20-02-25 23-02-20 24-04-23 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2022 2023 2024 2025
Net sales 1 448.9 - 1,366 2,025 2,421
EBITDA 93.78 - - - -
EBIT 1 77.3 - -53.2 257 321
Operating Margin 17.22% - -3.9% 12.69% 13.26%
Earnings before Tax (EBT) 1 76.97 - -59.1 255 319
Net income 1 66.16 362.9 -33.21 236 298
Net margin 14.74% - -2.43% 11.65% 12.31%
EPS 2 0.5444 2.986 -0.2600 1.760 2.210
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 20-02-25 23-02-20 24-04-23 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2022 2023 2024 2025
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) 8.65% - -1.75% 8% 9.2%
ROA (Net income/ Total Assets) 7.23% - - - -
Assets 1 915.7 - - - -
Book Value Per Share 2 8.170 - 18.60 21.90 24.00
Cash Flow per Share 2 0.4800 - 0.2500 1.910 2.870
Capex 97.4 - - - -
Capex / Sales 21.69% - - - -
Announcement Date 20-02-25 23-02-20 24-04-23 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
40
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SHANGHAI MEDICILON INC. Stock Shanghai Medicilon Inc.
-41.50% 778M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.99% 108B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.25% 105B
ARGENX SE Stock argenx SE
+1.57% 23.46B
BIONTECH SE Stock BioNTech SE
-12.23% 21.72B
GENMAB A/S Stock Genmab A/S
-7.05% 18.64B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.64% 17.45B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.58% 17.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.25% 13.99B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.87% 12.53B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 688202 Stock
  4. Financials Shanghai Medicilon Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW